Aegis Life develops nucleic acid-based vaccines and therapeutics using the Fusogenix Proteolipid Vehicle (PLV) delivery platform, which enhances the effective delivery of genetic payloads into target cells. The company addresses the challenge of preventing and treating infectious diseases by rapidly prototyping and scaling vaccine production for both existing and emerging pathogens.

Alt Legal provides an automated trademark docketing software that integrates with over 180 global jurisdictions to streamline the management of intellectual property filings. By offering features such as personalized reminders and one-click reporting, the platform reduces administrative burdens and enhances efficiency for law firms and companies managing trademark portfolios.

Dieta utilizes proprietary stool image recognition technology to convert images of bowel movements into objective clinical data, providing a precise measurement of digestive health. The platform offers personalized insights and recommendations for individuals suffering from irritable bowel syndrome (IBS), helping them navigate treatment options effectively.

Hera Biotech is commercializing MetriDx™, the first non-surgical diagnostic test for the definitive diagnosis and staging of endometriosis, utilizing micro-fluidic analysis of single cells from uterine brush biopsies. This technology addresses the limitations of current laparoscopic surgical methods, which can miss up to half of endometriosis lesions, by providing accurate and timely diagnoses that can significantly reduce healthcare costs and improve patient outcomes.

The startup develops digital health software that utilizes biofeedback therapy delivered via smartphones to help patients manage migraine symptoms. By teaching users to control physiological responses, the software aims to decrease the frequency and intensity of migraine attacks, chronic pain, and stress.

Kegg is a medical-grade fertility tracking device that utilizes cervical fluid sensing technology to provide accurate predictions of a user's fertile window in just two minutes a day. By focusing on cervical fluid changes, Kegg offers a more precise alternative to basal body temperature tracking, helping users optimize their conception efforts.

Oisin Biotechnologies develops genetic therapies utilizing Fusogenix™ Proteo-Lipid Vehicle technology to deliver DNA and RNA payloads for the treatment of age-related diseases. Their pipeline includes programs targeting frailty by promoting muscle growth, selectively eliminating fat cells, and removing senescent cells.

OncoSenX develops transient gene therapies that utilize a novel Proteo-Lipid Vehicle to deliver plasmid DNA, inducing apoptosis in transcriptionally active cancer cells. This targeted approach aims to treat solid tumors with reduced side effects, providing a less invasive alternative to traditional cancer therapies.

Re is an on‑chain reinsurance protocol that tokenizes real reinsurance treaties, issuing fully collateralized tokens backed by verified insurance premiums. The platform provides institutional investors and insurers with regulated, transparent access to the $800B+ reinsurance market, delivering 8‑16% annual yields that are largely uncorrelated with traditional assets while maintaining defined risk limits and underwriting discipline.

Truelytics provides an Advisor Transition Management Platform that utilizes data analytics to help wealth management and insurance firms streamline the recruitment, succession planning, and practice management processes. By offering real-time benchmarking and performance metrics, the platform enables enterprises to reduce transition costs and enhance business growth.